Kumar S, Ali I, Abbas F, Rana A, Pandey S, Garg M, Kumar D.
design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer. J Biomol Struct Dyn. 2023:1-23.